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Abstract
Introduction: There is little information about the risk of HCV recurrence in immunosuppressed
patients. Although the presence of antibodies to HCV and the absence of HCV-RNA is usually
considered to indicate viral elimination, the virus may not be completely eliminated but may be
under control of an effective immune response.
Case presentation: A 69 year old man presented with jaundice, elevated ALT, AST, lipase and
concomitant abdominal pain. He was found to be positive for HCV-RNA (genotype 3a) and was
diagnosed with acute hepatitis C. Six weeks later no HCV-RNA was detected, and the patient was
diagnosed with hyperthyreosis and started on propylthiouracil. After 4 weeks of propylthiouracil
treatment, the patient developed leucocytopenia, followed by liver function deterioration and
reappearance of HCV-RNA. Propylthiouracil was discontinued and his leukocyte counts increased.
Twenty-eight weeks after onset of acute hepatitis C, no HCV-RNA was detected.
Conclusion: This case history shows the risk of recurrence of HCV during leucocytopenia. These
findings indicate that patients who are anti-HCV positive but HCV-RNA negative may be at risk of
cytopenia-induced HCV reactivation.
Introduction
Spontaneous clearance of hepatitis C virus is highly
associated with a strong T lymphocyte response [1,2]. It is
unclear, however, if the virus is completely eliminated or
is present but under the control of the immune response.
Analogous to other viral diseases (e.g. HBV), it is likely
that traces of the virus remain in the body [3-5]. We
describe here the case of a 69 year old man with acute hep-
atitis C virus infection who developed propylthiouracil-
induced leucocytopenia, followed by cytopenia-induced
HCV recurrence. With recovery of leucocytes the virus was
again cleared spontaneously. These findings suggest that
agranulocytosis can lead to reactivation of hepatitis C
virus and that recovery from hepatitis C is not equivalent
to complete viral clearance. Therefore HCV reactivation
has to be considered in the diagnosis of patients positive
for anti-HCV antibodies but negative for HCV-RNA who
experience leucocytopenia for any reason.
Case presentation
A 69 year old man was admitted to an external hospital
due to jaundice. On the basis of cholestatic laboratory
findings with elevated lipase and concomitant abdominal
pain, an endoscopic retrograde cholangiopancreatogra-
phy (ERCP) was performed. Trapped air in CT scan indi-
cated a small perforation after papillotomy. In addition
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the patient developed post ERCP pancreatitis with signs of
peritonitis. He was therefore admitted to our intensive
care unit. At admission the following laboratory parame-
ters were out of range: ALT 1637 U/l (normal range < 45
U/l), AST 717 U/l (normal range < 40 U/l), and bilirubin
19 mg/dl (normal range < 1 mg/dl). During the following
days, his prothrombin time dropped to 34%. He was sub-
sequently shown to be positive for HCV-RNA (genotype
3a) and diagnosed with acute hepatitis C. Other coexist-
ing infections, metabolic or toxic liver diseases were ruled.
The patient recovered from the perforation and pancreati-
tis without surgical intervention.
Six weeks after onset of acute hepatitis, he was negative for
serum HCV RNA (Table 1). At this time, he was diagnosed
with hyperthyreosis and started on propylthiouracil 50
mg three times daily. The patient developed leucocytope-
nia, followed by worsening of liver function, 10 weeks
after the onset of acute hepatitis (Table 1). His AST and
ALT were normal, but his bilirubin had increased. Pro-
pylthiouracil treatment was stopped and his leukocyte
count recovered at week 12. Twenty weeks after onset of
acute disease, HCV-RNA was detected, at a concentration
of 140,000 IU/ml, at which time his AST (388 U/ml) and
ALT (371 U/ml) were increased markedly. Seven weeks
later, he was again negative for HCV-RNA without antivi-
ral treatment, and his liver enzymes had again normal-
ized. 47 weeks after onset of acute hepatitis HCV-RNA was
still negative indicating sustained spontaneous viral
clearance.
Retrospective our diagnosis of acute hepatitis C was there-
fore supported by several data. Patients wife was diag-
nosed with acute hepatitis C two weeks later. During
follow-up both had a documented spontaneous viral
elimination. As a possible mode of infection both had
made an ozone therapy at an alternative practitioner sev-
eral weeks before onset of acute disease.
Discussion and conclusion
Anti-HCV positive patients without HCV-RNA
(>6 months) are considered cured of hepatitis C. These
patients have either cleared the virus spontaneously or
after treatment. It is generally believed that hepatitis C
virus is not completely eliminated from the body but is
under control of the immune system. HCV-RNA has been
reported to be present in the liver and peripheral blood
mononuclear cells [3-5] of patients with no detectable
serum HCV-RNA. The clinical relevance of this phenom-
enon is unclear. Chemotherapy has been shown to
increase serum transaminase concentrations in HCV-
RNA positive patients, an increase thought to be due to
immunosuppression [6]. To date, however, only one case
report has described HCV RNA recurrence after chemo-
therapy [7]. Our case shows the risk of HCV recurrence
due to leucocytopenia caused by reasons other than
chemotherapy. Patients positive for anti-HCV antibodies
but negative for HCV-RNA are therefore at risk of HCV
reactivation due to cytopenia. Our findings also empha-
size the importance of virus specific T cell responses in
viral diseases. Thus, HCV recurrence should be consid-
ered in the differential diagnosis of anti-HCV positive
patients who experience cytopenia.
In summary, our findings indicate that greater attention
should be paid to liver function tests, not only in patients
chronically infected with HCV but in HCV-RNA negative
patients with a previous history of hepatitis C virus
infection.
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ERCP: Endoscopic retrograde cholangiopancreatography.




Week 1 Week 6 Week 10 Week 21 Week 28 Week 47
Leukocytes (4.0–
11.0 G/l)
19.8 G/l 9.0 G/l 0.6 G/l 4.7 G/l 5.3 G/l 5.1 G/l
ALT (< 45 U/l) 1637 U/l 119 U/l 35 U/l 371 U/l 25 U/l 27 U/l
AST (<40 U/l) 717 U/l 103 U/l 23 U/l 388 U/l 25 U/l 21 U/l
Bilirubin (<1.0 mg/dl) 19.0 mg/dl 11.4 mg/dl 7.9 mg/dl 1.8 mg/dl 1.1 mg/dl 0.9 mg/dl
Prothrombin time 
(70–100%)
44% 65% 50% 65% 70% 75%
HCV-RNA 
(negative)
2.300.000 IU/ml negative n.t. 140.000 IU/ml negative negative
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